Open an account

Vicapsys Life Sciences

VICP · OTC

$0.40+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About VICP

Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery, and others.

Employees
2
Headquarters
Cumming, Georgia
Listed
Jul 11, 2001
Sector
Health Care
Industry
Biotechnology
Website
vicapsys.com

VICP key statistics

Market cap
12.95M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
445
Volume
500
Open price
$0.40
High today
$0.40
Low today
$0.40
52 Week high
$1.75
52 Week low
$0.15

Vicapsys Life Sciences (VICP) at a glance

As of Oct 16, 2026, Vicapsys Life Sciences (VICP) shares are priced at $0.40, giving the company a market cap of 12.95M and a price-to-earnings ratio of 0.00.

Volume so far is 500 shares, in line with the average of 445 shares a day.

Over the past year Vicapsys Life Sciences has ranged from $0.15 to $1.75, and now sits 16% of the way up that range.

VICP news

  • Press releaseACCESS Newswire

    Housekeeping Starts with Branding: Vicapsys Life Sciences Adopts New Corporate Identity Developed by FutureBrand for Vicapsys and Its Stateline Subsidiary

  • Press releaseACCESS Newswire

    RETRANSMISSION: Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist(R), Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal and Underserved Markets

  • Press releaseACCESS Newswire

    Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist(R), Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal and Underserved Markets

Similar companies

Companies in the same industry as Vicapsys Life Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.